BioCryst Pharmaceuticals (NASDAQ:BCRX) Receives “Buy” Rating from Needham & Company LLC

Needham & Company LLC reaffirmed their buy rating on shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) in a research report sent to investors on Wednesday, Benzinga reports. They currently have a $12.00 price target on the biotechnology company’s stock.

BioCryst Pharmaceuticals Stock Up 1.5 %

Shares of BioCryst Pharmaceuticals stock opened at $4.87 on Wednesday. The stock’s fifty day moving average is $5.30 and its 200-day moving average is $5.72. The firm has a market capitalization of $1.00 billion, a PE ratio of -4.13 and a beta of 1.90. BioCryst Pharmaceuticals has a 12-month low of $4.45 and a 12-month high of $9.06.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its earnings results on Monday, February 26th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.04). The firm had revenue of $93.40 million during the quarter, compared to the consensus estimate of $89.19 million. Analysts expect that BioCryst Pharmaceuticals will post -0.62 EPS for the current year.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the stock. Fifth Third Bancorp raised its position in BioCryst Pharmaceuticals by 17,500.0% during the third quarter. Fifth Third Bancorp now owns 3,520 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 3,500 shares during the period. China Universal Asset Management Co. Ltd. raised its position in BioCryst Pharmaceuticals by 96.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 4,865 shares of the biotechnology company’s stock valued at $34,000 after buying an additional 2,388 shares during the period. Fairfield Bush & CO. acquired a new position in BioCryst Pharmaceuticals during the first quarter valued at $34,000. State of Wyoming acquired a new position in BioCryst Pharmaceuticals during the fourth quarter valued at $35,000. Finally, Advisory Services Network LLC raised its position in BioCryst Pharmaceuticals by 46.3% during the first quarter. Advisory Services Network LLC now owns 4,740 shares of the biotechnology company’s stock valued at $40,000 after buying an additional 1,500 shares during the period. 85.88% of the stock is owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.